BC Week In Review | Apr 15, 2013
Company News

Neoprobe management update

Neoprobe Corp. (NEOP), Dublin, Ohio   Business: Cancer, Diagnostics/Imaging   Hired: Larry Anderson, as VP and managing director, Europe; formerly first partner-in-charge of audit of Coopers & Lybrand L.L.P. in Russia  ...
BC Week In Review | Apr 15, 2013
Clinical News

Neoprobe regulatory update

NEOP submitted a BLA to the FDA for RIGScan CR49 (125I-labeled monoclonal antibody) for the intraoperative detection of metastatic colorectal cancer. The MAb is used with NEOP's RIGS cancer detection technology, which combines cancer-specific targeting...
BC Week In Review | Apr 15, 2013
Clinical News

Neoprobe regulatory update

The Ohio State University Research Foundation received U.S. Patent No. 5,590,656 covering a method of using somatostatin analogs for the surgical detection of cancer. NEOP has an exclusive license to the patent. The peptides are...
BC Week In Review | Apr 15, 2013
Company News

Neoprobe sales and marketing update

NEOP began selling the Neoprobe 1500 Portable Radioisotope Detector, a hand-held device that detects gamma rays and can be used to track an injected radiopharmaceutical. NEOP will sell the product through its 14-member sales team....
BC Week In Review | Jan 21, 2013
Company News

Navidea, AstraZeneca deal

Navidea said it and AstraZeneca added rights to two beta amyloid imaging agents - AZD2184 and AZD2995 - to a 2011 deal granting Navidea (formerly Neoprobe Corp. ) exclusive, worldwide rights to AZD4694 to detect Alzheimer's disease. The...
BC Week In Review | Apr 9, 2012
Clinical News

Lymphoseek tilmanocept regulatory update

FDA extended the PDUFA date by 90 days for diagnostic product Lymphoseek tilmanocept from Navidea (formerly Neoprobe Corp. ) to Sept. 10 from June 10. The NDA is under review for use in intraoperative lymphatic mapping....
BC Extra | Apr 4, 2012
Company News

FDA delays Lymphoseek decision

FDA extended the PDUFA date by three months for an NDA from Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB) for Lymphoseek tilmanocept for use in intraoperative lymphatic mapping. The new date is Sept. 10; it was June 10....
BC Week In Review | Jan 9, 2012
Financial News

Navidea completes private placement of convertible notes and warrants

Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB), Dublin, Ohio   Business: Diagnostic   Date completed: 1/4/12   Type: Private placement of convertible notes and warrants   Raised: $7 million   Shares outstanding prior: 95.1 million   Investor: Hercules...
BC Week In Review | Dec 19, 2011
Company News

Neoprobe, AstraZeneca deal

AstraZeneca granted Neoprobe exclusive, worldwide rights to AZD4694 , a late-stage radiopharmaceutical imaging agent that binds to beta amyloid deposits to detect Alzheimer's disease. AstraZeneca received $5 million up front, and is eligible for $6.5 million...
BC Week In Review | Oct 24, 2011
Clinical News

Lymphoseek tilmanocept regulatory update

FDA accepted for review an NDA from Neoprobe for Lymphoseek tilmanocept for use in intraoperative lymphatic mapping (ILM). The NDA for theTc99m-labeled radioactive tracing agent was submitted on Aug. 10. A standard 10-month review would...
Items per page:
1 - 10 of 186
BC Week In Review | Apr 15, 2013
Company News

Neoprobe management update

Neoprobe Corp. (NEOP), Dublin, Ohio   Business: Cancer, Diagnostics/Imaging   Hired: Larry Anderson, as VP and managing director, Europe; formerly first partner-in-charge of audit of Coopers & Lybrand L.L.P. in Russia  ...
BC Week In Review | Apr 15, 2013
Clinical News

Neoprobe regulatory update

NEOP submitted a BLA to the FDA for RIGScan CR49 (125I-labeled monoclonal antibody) for the intraoperative detection of metastatic colorectal cancer. The MAb is used with NEOP's RIGS cancer detection technology, which combines cancer-specific targeting...
BC Week In Review | Apr 15, 2013
Clinical News

Neoprobe regulatory update

The Ohio State University Research Foundation received U.S. Patent No. 5,590,656 covering a method of using somatostatin analogs for the surgical detection of cancer. NEOP has an exclusive license to the patent. The peptides are...
BC Week In Review | Apr 15, 2013
Company News

Neoprobe sales and marketing update

NEOP began selling the Neoprobe 1500 Portable Radioisotope Detector, a hand-held device that detects gamma rays and can be used to track an injected radiopharmaceutical. NEOP will sell the product through its 14-member sales team....
BC Week In Review | Jan 21, 2013
Company News

Navidea, AstraZeneca deal

Navidea said it and AstraZeneca added rights to two beta amyloid imaging agents - AZD2184 and AZD2995 - to a 2011 deal granting Navidea (formerly Neoprobe Corp. ) exclusive, worldwide rights to AZD4694 to detect Alzheimer's disease. The...
BC Week In Review | Apr 9, 2012
Clinical News

Lymphoseek tilmanocept regulatory update

FDA extended the PDUFA date by 90 days for diagnostic product Lymphoseek tilmanocept from Navidea (formerly Neoprobe Corp. ) to Sept. 10 from June 10. The NDA is under review for use in intraoperative lymphatic mapping....
BC Extra | Apr 4, 2012
Company News

FDA delays Lymphoseek decision

FDA extended the PDUFA date by three months for an NDA from Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB) for Lymphoseek tilmanocept for use in intraoperative lymphatic mapping. The new date is Sept. 10; it was June 10....
BC Week In Review | Jan 9, 2012
Financial News

Navidea completes private placement of convertible notes and warrants

Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB), Dublin, Ohio   Business: Diagnostic   Date completed: 1/4/12   Type: Private placement of convertible notes and warrants   Raised: $7 million   Shares outstanding prior: 95.1 million   Investor: Hercules...
BC Week In Review | Dec 19, 2011
Company News

Neoprobe, AstraZeneca deal

AstraZeneca granted Neoprobe exclusive, worldwide rights to AZD4694 , a late-stage radiopharmaceutical imaging agent that binds to beta amyloid deposits to detect Alzheimer's disease. AstraZeneca received $5 million up front, and is eligible for $6.5 million...
BC Week In Review | Oct 24, 2011
Clinical News

Lymphoseek tilmanocept regulatory update

FDA accepted for review an NDA from Neoprobe for Lymphoseek tilmanocept for use in intraoperative lymphatic mapping (ILM). The NDA for theTc99m-labeled radioactive tracing agent was submitted on Aug. 10. A standard 10-month review would...
Items per page:
1 - 10 of 186